Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations. - Wikidata - wikimedia - TriplyDB

Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations.

Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations.

http://www.wikidata.org/entity/Q33803999

about

Slow drug delivery decreased total body clearance and altered bioavailability of immediate- and controlled-release oxycodone formulations Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets.

P2860

Q38762087-F214B6EB-ED01-400B-99FD-B3BCD3BB8C46 Q50606382-08712566-BC6C-4C1C-B756-0ECA94EA4B26

P2860

Statistical comparison of dissolution profiles to predict the bioequivalence of extended release formulations.

http://www.wikidata.org/entity/Q33803999

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Statistical comparison of diss ...... extended release formulations.

@ast

Statistical comparison of diss ...... extended release formulations.

@en

type

label

Statistical comparison of diss ...... extended release formulations.

@ast

Statistical comparison of diss ...... extended release formulations.

@en

prefLabel

Statistical comparison of diss ...... extended release formulations.

@ast

Statistical comparison of diss ...... extended release formulations.

@en

P1433

Q33803999-5AC188E4-71E3-47D4-AB01-CA0036DB8C84

P1476

Q33803999-C1CEB491-49DC-442F-8404-6FB2563D1922

P2093

Q33803999-3DD84F31-B5BB-4135-BAF3-7C06C3996895

Q33803999-7A4F7842-8354-41F9-8B11-CB8490B2F2BE

Q33803999-9D1375AD-D2D7-459B-8A0C-057DA57D690F

Q33803999-BF8210D5-0121-4C9C-9FB0-564AB877DB5A

Q33803999-E61F87C4-6B3A-440C-8F92-C9954B8DCF68

P2860

Q33803999-109B0E51-CC75-4C4C-8D53-0F82A4B0EB89

Q33803999-15BCBBF6-BD1E-4EBC-BE17-0B5BC4A48D99

Q33803999-241A72CD-2D8A-4443-BEE8-1A974C75555B

Q33803999-27BB066A-3C27-4D84-8C7D-BD785518F8F3

Q33803999-2807964C-ACD0-41C2-91E0-62FF006BD30F

Q33803999-2881EAF0-1BD8-465F-9D1A-18B6EF781593

Q33803999-2FC4DAAD-F152-45FF-9862-1196B7B1044E

Q33803999-319F3390-E820-4B67-81A3-0EBE906C1E4E

Q33803999-44990080-5DA4-4061-926D-902ABA217B3F

Q33803999-55E3B529-1EF0-4402-B4BC-DA9622B0E3E7

P2888

Q33803999-44607E23-B38B-4AB8-A14D-C6B01380143F

P304

Q33803999-F4E65042-D5AF-4B79-9B6B-775B12BA9BA9

P31

Q33803999-03C27F0A-2174-4231-8CB7-8CF73A30B27C

P356

Q33803999-2D51F3C8-AC2A-44E0-BB83-2D905231BCFF

P407

Q33803999-172AD7CE-DC7B-447C-ACC8-2880B1B09AB7

P433

Q33803999-1E5689C2-5036-4685-865E-C3B38D50A16B

P478

Q33803999-FD5043A8-F290-475F-B977-114F99139FFA

P577

Q33803999-88B2AF7E-5C69-4D3D-8398-9D358B06F7A0

P5875

Q33803999-FD426AD1-85E5-4F54-B359-D4A3E00FE799

P6179

Q33803999-33075A0D-4B09-4814-8BA7-05CE0C0C148B

P698

Q33803999-A026957E-1BDB-4997-B90A-7B3F99B42572

P921

Q33803999-473552D1-639B-46E1-9308-1015ECDFF7B3

P932

Q33803999-7EF8101E-31E1-4986-BAA8-E18FD3D6EBED

P356

S12248-014-9615-6

P1433

The AAPS Journal

P1476

Statistical comparison of diss ...... extended release formulations.

@en

P2093

C M Lehr

http://www.w3.org/2001/XMLSchema#string

J D Gomez-Mantilla

http://www.w3.org/2001/XMLSchema#string

T Lehr

http://www.w3.org/2001/XMLSchema#string

U F Schaefer

http://www.w3.org/2001/XMLSchema#string

V G Casabo

http://www.w3.org/2001/XMLSchema#string

P2860

Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit

Conformational analysis of StrH, the surface-attached exo-β-D-N-acetylglucosaminidase from Streptococcus pneumoniae

Analysis of dissolution data using modified versions of Noyes-Whitney equation and the Weibull function.

Modeling and comparison of dissolution profiles.

An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.

Bioequivalence requirements in the European Union: critical discussion

Review of global regulations concerning biowaivers for immediate release solid oral dosage forms.

Estimating drug solubility in the gastrointestinal tract.

Review of methodologies for the comparison of dissolution profile data.

Bioavailability and bioequivalence: focus on physiological factors and variability.

P2888

s12248-014-9615-6

P304

791-801

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-014-9615-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262608801

http://www.w3.org/2001/XMLSchema#string

P6179

1049710717

http://www.w3.org/2001/XMLSchema#string

P698

24854895

http://www.w3.org/2001/XMLSchema#string

P921

P932

4070268

http://www.w3.org/2001/XMLSchema#string